{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:59:40Z","timestamp":1788371980423,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017956","name":"Health Commission of Gansu Province","doi-asserted-by":"publisher","award":["GSWSKY-2019-51"],"award-info":[{"award-number":["GSWSKY-2019-51"]}],"id":[{"id":"10.13039\/100017956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["Clinical Medical Research Center"],"award-info":[{"award-number":["Clinical Medical Research Center"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["21JR7RA437"],"award-info":[{"award-number":["21JR7RA437"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009590","name":"Gansu Education Department","doi-asserted-by":"publisher","award":["2020B-060"],"award-info":[{"award-number":["2020B-060"]}],"id":[{"id":"10.13039\/501100009590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022817","name":"Lanzhou University Second Hospital","doi-asserted-by":"publisher","award":["CY2019-HL14"],"award-info":[{"award-number":["CY2019-HL14"]}],"id":[{"id":"10.13039\/100022817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10067-024-07084-2","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T14:22:05Z","timestamp":1722608525000},"page":"2807-2815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of disease duration on the use of tofacitinib: a real-world study in elderly patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"43","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-6419","authenticated-orcid":false,"given":"Hai-Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"issue":"24","key":"7084_CR1","first-page":"2120","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor K (2012) FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 69(24):2120","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"7084_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"Du Pan","year":"2009","unstructured":"Pan Du, Dehler C et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61(5):560\u2013568","journal-title":"Arthritis Rheum"},{"issue":"2","key":"7084_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/mr\/roab003","volume":"32","author":"K Ebina","year":"2022","unstructured":"Ebina K (2022) Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis. Mod Rheumatol 32(2):256\u2013262","journal-title":"Mod Rheumatol"},{"issue":"1","key":"7084_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semarthrit.2012.02.004","volume":"42","author":"S-K Cho","year":"2012","unstructured":"Cho S-K, Sung Y-K, Choi C-B et al (2012) Do patients with elderly-onset rheumatoid arthritis have severe functional disability? Semin Arthritis Rheum 42(1):23\u201331","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"7084_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M et al (2016) Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken) 68(4):432\u2013439","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"7084_CR6","first-page":"485","volume":"37","author":"Z Caporali","year":"2019","unstructured":"Caporali Z (2019) Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 37(3):485\u2013495","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"7084_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/acr2.11468","volume":"4","author":"AJ Cordisco","year":"2022","unstructured":"Cordisco AJ, Olave M, George MD et al (2022) Identifying factors associated with treatment response in rheumatoid arthritis clinical trials. ACR Open Rheumatol 4(9):811\u2013818","journal-title":"ACR Open Rheumatol"},{"key":"7084_CR8","doi-asserted-by":"publisher","unstructured":"Barbich T, Cerda OL, Schneeberger EE, Citera G (2021) Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice. Reumatol Clin (Engl Ed) English, Spanish. S1699-258X(20)30274\u201330276.\u00a0 https:\/\/doi.org\/10.1016\/j.reuma.2020.11.003","DOI":"10.1016\/j.reuma.2020.11.003"},{"issue":"Suppl 2","key":"7084_CR9","first-page":"ii13","volume":"63","author":"F Wolfe","year":"2004","unstructured":"Wolfe F (2004) Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 63(Suppl 2):ii13\u2013ii17","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7084_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10067-015-3031-x","volume":"35","author":"TN Ruban","year":"2016","unstructured":"Ruban TN, Jacob B, Pope JE et al (2016) The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clin Rheumatol 35(3):759\u2013763","journal-title":"Clin Rheumatol"},{"issue":"2","key":"7084_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40744-022-00511-3","volume":"10","author":"R Fleischmann","year":"2023","unstructured":"Fleischmann R, Haraoui B, Buch MH et al (2023) Analysis of disease activity metrics in a methotrexate withdrawal study among patients with rheumatoid arthritis treated with tofacitinib plus methotrexate. Rheumatol Ther 10(2):375\u2013386","journal-title":"Rheumatol Ther"},{"issue":"10","key":"7084_CR12","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s10067-020-05087-3","volume":"39","author":"F Navarro","year":"2020","unstructured":"Navarro F, Martinez-Sesmero JM, Balsa A et al (2020) Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol 39(10):2919\u20132930","journal-title":"Clin Rheumatol"},{"issue":"10","key":"7084_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s12325-018-0757-2","volume":"35","author":"P Emery","year":"2018","unstructured":"Emery P, Pope JE, Kruger K et al (2018) Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review. Adv Ther 35(10):1535\u20131563","journal-title":"Adv Ther"},{"key":"7084_CR14","unstructured":"Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, Jones TV (2017) Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol 35(3):390\u2013400"},{"issue":"2","key":"7084_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1756-185X.13244","volume":"21","author":"Z Li","year":"2018","unstructured":"Li Z, An Y, Houheng S et al (2018) Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: patient-reported outcomes from a Phase 3 randomized controlled trial. Int J Rheum Dis 21(2):402\u2013414","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"7084_CR16","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s10067-022-06205-z","volume":"41","author":"S Phatak","year":"2022","unstructured":"Phatak S, Khenat A, Malandkar M et al (2022) Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India. Clin Rheumatol 41(10):2961\u20132966","journal-title":"Clin Rheumatol"},{"issue":"7","key":"7084_CR17","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","volume":"95","author":"F Wang","year":"2020","unstructured":"Wang F, Sun L, Wang S et al (2020) Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc 95(7):1404\u20131419","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"7084_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73(7):924\u2013939","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7084_CR19","doi-asserted-by":"publisher","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H (2019) Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One 14(5):e0216624. https:\/\/doi.org\/10.1371\/journal.pone.0216624","DOI":"10.1371\/journal.pone.0216624"},{"key":"7084_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/rmdopen-2021-001673","volume":"7","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, Pope J, Haraoui B et al (2021) Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b\/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD Open 7:2","journal-title":"RMD Open"},{"key":"7084_CR21","unstructured":"Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, Kvien TK, Minnock P, Newman SP, Quest EM, Taal E, Wale J (2005) Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. J Rheumatol 32(11):2250\u20132256"},{"issue":"8","key":"7084_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/acr.20188","volume":"62","author":"W Katchamart","year":"2010","unstructured":"Katchamart W, Johnson S, Lin H-JL et al (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 62(8):1128\u20131143","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"7084_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10067-018-4340-7","volume":"38","author":"Y Chen","year":"2019","unstructured":"Chen Y, Jin S, Wang Y et al (2019) Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol 38(3):727\u2013738","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07084-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07084-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07084-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T09:11:48Z","timestamp":1723885908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07084-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7084"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07084-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with International Council for Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. The study protocol was reviewed and approved by the Institutional Review Boards and\/or an independent ethics committee at each study center, approval number 2023A-489. Because of the retrospective nature of the study, the requirement of informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}